KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

BACKGROUND: KRAS is mutated in ∼30% of non-small-cell lung cancer (NSCLC) but it has also been identified as one of the mechanisms underlying resistance to tyrosine kinase inhibitors (TKIs) in EGFR-positive NSCLC patients. Novel KRAS inhibitors targeting KRAS p.G12C mutation have been developed rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Serna-Blasco, R., Sánchez-Herrero, E., Sanz-Moreno, S., Rodriguez-Festa, A., García-Veros, E., Casarrubios, M., Sierra-Rodero, B., Laza-Briviesca, R., Cruz-Bermúdez, A., Mielgo-Rubio, X., Sánchez-Hernández, A., Uribelarrea, E.A., Calvo, V., Romero, A., Provencio, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493588/
https://www.ncbi.nlm.nih.gov/pubmed/34607284
http://dx.doi.org/10.1016/j.esmoop.2021.100279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493588/
https://www.ncbi.nlm.nih.gov/pubmed/34607284
http://dx.doi.org/10.1016/j.esmoop.2021.100279

Ejemplares similares